Daclatasvir-d6

Product Description
CAT No.
ALN-D036D01
CAS No.
1801709-41-0
Mol. F.
C40H44D6N8O6
Mol. Wt.
744.9
Stock
Please Inquire
Product Overview
Technical Data
Reference
RFQ
Product Overview
Chemical Name : N,N’-[[1,1’-Biphenyl]-4,4’-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-carbamic Acid C,C’-Dimethyl Ester-d6;
Smiles : O=C([C@@H](NC(OC([2H])([2H])[2H])=O)C(C)C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C4=CC=C(C5=CN=C([C@@H]6CCCN6C([C@@H](NC(OC([2H])([2H])[2H])=O)C(C)C)=O)N5)C=C4)C=C3
Inchi : InChI=1S/C20H29N5O4/c1-24(19(26)15-7-5-10-29-15)8-6-9-25(2)20-22-14-12-17(28-4)16(27-3)11-13(14)18(21)23-20/h11-12,15H,5-10H2,1-4H3,(H2,21,22,23)/t15-/m1/s1
Technical Data
Reference
A validated stability-indicating reverse-phase high-performance liquid chromatography method for daclatasvir, identification and characterization of degradation products using LC-ESI-QTOF-MS
By Warghade, Snehal V.; Bothara, Kailash G.nFrom Asian Journal of Pharmaceutical and Clinical Research (2019), 12(5), 302-308
Development and validation of HPLC fluorescence and UPLC/DAD stability-indicating methods for determination of hepatitis C antiviral agent daclatasvir
By Kamal, Andra H.; Ismail, Nahla S.; Mabroijk, Mokhtar M.; Bebawy, Lories I.; Mekky, Mai A. – From Journal of AOAC International (2019), 102(4), 1125-1131
A stability-indicating UPLC method for the determination of potential impurities and its mass by a new QDa mass detector in daclatasvir drug used to treat hepatitis C infection
By Jagadabi, Varaprasad; Kumar, P. V. Nagendra; Mahesh, Kasthuri; Pamidi, Srinivasu; Ramaprasad, L. A.; Nagaraju, D. – From Journal of Chromatographic Science (2019), 57(1), 44-53
RFQ